MKI67 and neoplasm: The group receiving systemic treatment exhibited a significantly higher rate of advanced tumor stages, incomplete resection status, elevated Ki-67 levels, greater frequency of relapse, fewer cases of complete remission and a higher incidence of metastasized tumors compared to the group not treated with systemic therapy (all P < 0.05).